Dopamine-β-hydroxylase (DBH, EC 1.14.17.1), which converts dopamine to norepinephrine, is a candidate gene in neuropsychiatric diseases.
Aim:
To assess the effect of regulatory variants in DBH on schizophrenia and its endophenotypes –cognition and tardive dyskinesia.
Methods:
We tested association of functional variants 19bp Ins/Del, rs1989787 and rs1611115 in DBH with i) schizophrenia (1236 cases, 1136 controls), ii) tardive dyskinesia (83 positive, 162 negative) and iii) performance functions of cognition (357 cases, 306 controls) estimated by the Penn Computerized Neurocognitive Battery.
Results:
A modest haplotypic (Ins-C; 19bp Ins/Del – rs1989787 C>T; p=0.04) association was observed with schizophrenia. We observed ~39% reduction in activity of 19bp Del allele on luciferase assay. Analysis of covariance revealed interactions of tardive dyskinesia status and: i) 19bp Ins/Del (genotypic, p=0.04) and ii) rs1989787 and rs1611115 (combined genotypic, p=0.004) on Abnormal Involuntary Movement Scale total score. Association of rs1611115 with positive and negative syndrome scale (PANSS) total score (p=0.05) and allelic/genotypic association with lower positive (p=0.03/0.04), general psychopathology (p=0.01/0.01) PANSS scales in tardive dyskinesia-positive; and allelic/genotypic (p=0.02/0.05) with higher score of depressive factors in tardive dyskinesia-negative subgroups were observed. Analysis of covariance with continuous variable of cognition showed interaction of health status with: i) rs1989787 on accuracy and efficiency (p=0.03) of abstraction and mental flexibility; ii) rs1611115 on accuracy of working memory and emotion (p=0.05); iii) 19bp Ins/Del on processing speed of emotion (p=0.03). Allelic/genotypic association of rs1989787 with spatial ability (p=0.02–0.05) among healthy controls; association of rs1611115 with Global Assessment Scale scores in the past month (p=0.05) among schizophrenia subjects of cognition cohort was also observed.
Conclusions:
With modest genotype–phenotype correlations available for DBH variants, personalized treatment regimens based on DBH activity for ameliorating tardive dyskinesia and cognitive symptoms may be plausible.
AndreasenNCOlsenS (1982) Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry39: 789–794.
2.
AtesOCelikelFCTaycanSE, et al. (2013) Association between 1603C>T polymorphism of DBH gene and bipolar disorder in a Turkish population. Gene519: 356–359.
3.
BhatiaTAgarwalAShahG, et al. (2012) Adjunctive cognitive remediation for schizophrenia using yoga: An open, non-randomized trial. Acta Neuropsychiatr24: 91–100.
4.
BiedlerJLRoffler-TarlovSSchachnerM, et al. (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res38: 3751–3757.
5.
BraverTSBarchDMCohenJD (1999) Cognition and control in schizophrenia: A computational model of dopamine and prefrontal function. Biol Psychiatry46: 312–328.
6.
CaiJXMaYYXuL, et al. (1993) Reserpine impairs spatial working memory performance in monkeys: Reversal by the alpha 2-adrenergic agonist clonidine. Brain Res614: 191–196.
ChenYWenGRaoF, et al. (2010) Human dopamine beta-hydroxylase (DBH) regulatory polymorphism that influences enzymatic activity, autonomic function, and blood pressure. J Hypertens28: 76–86.
9.
ChenYZhangKWenG, et al. (2011) Human dopamine β-hydroxylase promoter variant alters transcription in chromaffin cells, enzyme secretion, and blood pressure. Am J Hypertens24: 24–32.
10.
CondrayRYaoJK (2011) Cognition, dopamine and bioactive lipids in schizophrenia. Front Biosci (Schol Ed)3: 298–330.
11.
CubellsJFZabetianCP (2004) Human genetics of plasma dopamine beta-hydroxylase activity: Applications to research in psychiatry and neurology. Psychopharmacology (Berl)174: 463–476.
12.
CubellsJFvan KammenDPKelleyME, et al. (1998) Dopamine beta-hydroxylase: Two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum Genet102: 533–540.
13.
DavisKLKahnRSKoG, et al. (1991) Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry148: 1474–1486.
14.
DeshpandeSNMathurMNDasSK, et al. (1998) A Hindi version of the diagnostic interview for genetic studies. Schizophr Bull24: 489–493.
15.
DyerBWFerrerFAKlinedinstDK, et al. (2000) A noncommercial dual luciferase enzyme assay system for reporter gene analysis. Anal Biochem282: 158–161.
16.
EndicottJSpitzerRLFleissJL, et al. (1976) The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry33: 766–771.
17.
FoxJWeisbergS (2011) An R Companion to Applied Regression. Los Angeles, CA; London: SAGE Publications.
18.
FriedmanJIAdlerDNDavisKL (1999) The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer’s disease. Biol Psychiatry46: 1243–1252.
19.
GamoNJWangMArnstenAF (2010) Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry49: 1011–1023.
20.
GaudermanWJMorrisonJM (2006) QUANTO 1.1: A Computer Program for Power and Sample Size Calculations for Genetic-epidemiology Studies. Available at: http://biostats.usc.edu/Quanto.html (accessed 13 September 2019).
21.
Gonzalez-LopezEVranaKE (2020) Dopamine beta-hydroxylase and its genetic variants in human health and disease. J Neurochem152: 157–181.
22.
GreenwoodTABraffDLLightGA, et al. (2007) Initial heritability analyses of endophenotypic measures for schizophrenia: The consortium on the genetics of schizophrenia. Arch Gen Psychiatry64: 1242–1250.
23.
GurRCRaglandJDMobergPJ, et al. (2001a) Computerized neurocognitive scanning: I. Methodology and validation in healthy people. Neuropsychopharmacology25: 766–776.
24.
GurRCRaglandJDMobergPJ, et al. (2001b) Computerized neurocognitive scanning: II. The profile of schizophrenia. Neuropsychopharmacology25: 777–788.
25.
GurRCRichardJHughettP, et al. (2010) A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: Standardization and initial construct validation. J Neurosci Methods187: 254–262.
26.
GurRENimgaonkarVLAlmasyL, et al. (2007) Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia. Am J Psychiatry164: 813–819.
27.
GuyW (1976) Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare, 534–537.
28.
HawkinsDMWeisbergS (2017) Combining the box-cox power and generalised log transformations to accommodate nonpositive responses in linear and mixed-effects linear models. S Afr Stat J51: 317–328.
29.
HeinrichsRWZakzanisKK (1998) Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology12: 426–445.
30.
HuiLHanMHuangXF, et al. (2015a) Possible association between DBH 19 bp insertion/deletion polymorphism and clinical symptoms in schizophrenia with tardive dyskinesia. J Neural Transm (Vienna)122: 907–914.
31.
HuiLHanMHuangXF, et al. (2016) Association between DbetaH 5’-insertion/deletion polymorphism and cognition in patients with chronic schizophrenia. J Clin Psychiatry77: 379–385.
32.
HuiLHanMYinGZ, et al. (2015b) Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia. Schizophr Res182: 104–109.
33.
HuiLZhangXHuangXF, et al. (2012) The dopamine b-hydroxylase 19 bp insertion/deletion polymorphism was associated with first-episode but not medicated chronic schizophrenia. J Psychiatr Res46: 733–737.
34.
HuiLZhangXYuYQ, et al. (2013) Association between DBH 19 bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients. Schizophr Res147: 236–240.
35.
IshiiAKobayashiKKiuchiK, et al. (1991) Expression of two forms of human dopamine-beta-hydroxylase in COS cells. Neurosci Lett125: 25–28.
36.
JentschJDAardeSMSeuE (2009) Effects of atomoxetine and methylphenidate on performance of a lateralized reaction time task in rats. Psychopharmacology (Berl)202: 497–504.
37.
JesteDVDeLisiLEZalcmanS, et al. (1981) A biochemical study of tardive dyskinesia in young male patients. Psychiatry Res4: 327–331.
KaufmannCAJesteDVSheltonRC, et al. (1986) Noradrenergic and neuroradiological abnormalities in tardive dyskinesia. Biol Psychiatry21: 799–812.
40.
KaySRFiszbeinAOplerLA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull13: 261–276.
41.
KimCHLeungAHuhYH, et al. (2011) Norepinephrine deficiency is caused by combined abnormal mRNA processing and defective protein trafficking of dopamine beta-hydroxylase. J Biol Chem286: 9196–9204.
42.
KlimekVRajkowskaGLukerSN, et al. (1999) Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology21: 69–81.
43.
KopeckovaMPacltIGoetzP (2006) Polymorphisms and low plasma activity of dopamine-beta-hydroxylase in ADHD children. Neuro Endocrinol Lett27: 748–754.
44.
KukshalPBhatiaTBhagwatAM, et al. (2013) Association study of neuregulin-1 gene polymorphisms in a North Indian schizophrenia sample. Schizophr Res144: 24–30.
45.
LamourouxAVignyAFaucon BiguetN, et al. (1987) The primary structure of human dopamine-beta-hydroxylase: Insights into the relationship between the soluble and the membrane-bound forms of the enzyme. EMBO J6: 3931–3937.
46.
LevinEYLevenbergBKaufmanS (1960) The enzymatic conversion of 3,4-dihydroxyphenylethylamine to norepinephrine. J Biol Chem235: 2080–2086.
47.
MeltzerHYGoodeDJFangVS, et al. (1976) Dopamine and schizophrenia. Lancet2: 1142.
48.
MustapicMMaihoferAXMahataM, et al. (2014) The catecholamine biosynthetic enzyme dopamine beta-hydroxylase (DBH): First genome-wide search positions trait-determining variants acting additively in the proximal promoter. Hum Mol Genet23: 6375–6384.
49.
NurnbergerJIJrBleharMCKaufmannCA, et al. (1994) Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry51: 849–859; discussion 863-844.
50.
ParasuramanRde VisserELinMK, et al. (2012) Dopamine beta hydroxylase genotype identifies individuals less susceptible to bias in computer-assisted decision making. PLoS One7: e39675.
51.
PardinasAFHolmansPPocklingtonAJ, et al. (2018) Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet50: 381–389.
52.
PunchaichiraTJDeshpandeSNThelmaBK (2018) Determination of dopamine-beta-hydroxylase activity in human serum using UHPLC-PDA detection. Neurochem Res 43: 2324–2332.
53.
PunchaichiraTJDeySKMukhopadhyayA, et al. (2017) Characterization of SNPs in the dopamine-beta-hydroxylase gene providing new insights into its structure-function relationship. Neurogenetics18: 155–168.
54.
PunchaichiraTJPrasadSDeshpandeSN, et al. (2016) Deep sequencing identifies novel regulatory variants in the distal promoter region of the dopamine-beta-hydroxylase gene. Pharmacogenet Genomics26: 311–323.
55.
PurcellSNealeBTodd-BrownK, et al. (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet81: 559–575.
56.
SakuraiHBiesRRStroupST, et al. (2013) Dopamine D2 receptor occupancy and cognition in schizophrenia: Analysis of the CATIE data. Schizophr Bull39: 564–574.
57.
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) Biological insights from 108 schizophrenia-associated genetic loci. Nature511: 421–427.
58.
SchoolerNRKaneJM (1982) Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry39: 486–487.
59.
SontagTAHauserJKaunzingerI, et al. (2008) Effects of the noradrenergic neurotoxin DSP4 on spatial memory in the rat. J Neural Transm (Vienna)115: 299–303.
60.
SrivastavaVDeshpandeSNThelmaBK. (2010) Dopaminergic pathway gene polymorphisms and genetic susceptibility to schizophrenia among north Indians. Neuropsychobiology61: 64–70.
61.
SternbergDEVanKammenDPLernerP, et al. (1982) Schizophrenia: Dopamine beta-hydroxylase activity and treatment response. Science216: 1423–1425.
62.
TangYLEpsteinMPAndersonGM, et al. (2007) Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans. Eur J Hum Genet15: 878–883.
63.
TiwariAKDeshpandeSNLererB, et al. (2007) Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. Pharmacogenomics J7: 305–311.
64.
TiwariAKDeshpandeSNRaoAR, et al. (2005a) Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res75: 21–26.
65.
TiwariAKDeshpandeSNRaoAR, et al. (2005b) Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J5: 60–69.
66.
ToulopoulouTGoldbergTEMesaIR, et al. (2010) Impaired intellect and memory: A missing link between genetic risk and schizophrenia?Arch Gen Psychiatry67: 905–913.
67.
TzavaraETBymasterFPOvershinerCD, et al. (2006) Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry11: 187–195.
68.
WagnerRLJesteDVPhelpsBH, et al. (1982) Enzyme studies in tardive dyskinesia. I. One-year biochemical follow-up. J Clin Psychopharmacol2: 312–314.
69.
WallworkRSFortgangRHashimotoR, et al. (2012) Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res137: 246–250.
70.
YamamotoKCubellsJFGelernterJ, et al. (2003) Dopamine beta-hydroxylase (DBH) gene and schizophrenia phenotypic variability: A genetic association study. Am J Med Genet B Neuropsychiatr Genet117B: 33–38.
71.
ZabetianCPAndersonGMBuxbaumSG, et al. (2001) A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: Evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet68: 515–522.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
